UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/560,378	01/22/2007	Toshiyuki Hori	58777.000018	9632
	7590 03/04/200 /ILLIAMS LLP	EXAMINER		
INTELLECTUAL PROPERTY DEPARTMENT			HAYES, ROBERT CLINTON	
SUITE 1200	STREET, N.W. 200		ART UNIT	PAPER NUMBER
WASHINGTO	N, DC 20006-1109	1649		
			MAIL DATE	DELIVERY MODE
			03/04/2009	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

	Application No.	Applicant(s)				
Office Action Occurrence	10/560,378	HORI, TOSHIYUK	1			
Office Action Summary	Examiner	Art Unit				
	Robert C. Hayes, Ph.D.	1649				
The MAILING DATE of this communication app Period for Reply	ears on the cover sheet with the c	orrespondence ad	dress			
A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING DA - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period w - Failure to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 16(a). In no event, however, may a reply be tim ill apply and will expire SIX (6) MONTHS from cause the application to become ABANDONEI	J. nely filed the mailing date of this co D (35 U.S.C. § 133).				
Status						
1) Responsive to communication(s) filed on						
	- action is non-final.					
3) Since this application is in condition for allowance except for formal matters, prosecution as to the						
closed in accordance with the practice under E	x parte Quayle, 1935 C.D. 11, 45	3 O.G. 213.				
Disposition of Claims						
4)⊠ Claim(s) <u>1-25</u> is/are pending in the application.						
4a) Of the above claim(s) is/are withdrawn from consideration.						
5) Claim(s) is/are allowed.						
6) Claim(s) is/are rejected.						
7) Claim(s) is/are objected to.						
8) Claim(s) <u>1-25</u> are subject to restriction and/or e	election requirement.					
Application Papers						
9)☐ The specification is objected to by the Examiner	t.					
10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.						
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).						
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).						
11)☐ The oath or declaration is objected to by the Exa	aminer. Note the attached Office	Action or form PT	O-152.			
Priority under 35 U.S.C. § 119						
12) ☐ Acknowledgment is made of a claim for foreign a) ☐ All b) ☐ Some * c) ☐ None of:		-(d) or (f).				
1. Certified copies of the priority documents						
2. Certified copies of the priority documents	• •	·	_			
3. Copies of the certified copies of the prior	•	ed in this National	Stage			
application from the International Bureau (PCT Rule 17.2(a)).						
* See the attached detailed Office action for a list of	of the certified copies not receive	a.				
Attachment(s)	_					
1) Notice of References Cited (PTO-892)	4) ☐ Interview Summary Paper No(s)/Mail Da					
2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO/SB/08)	5) Notice of Informal P					
Paper No(s)/Mail Date	6) Other:					

Application/Control Number: 10/560,378 Page 2

Art Unit: 1649

DETAILED ACTION

Election/Restrictions

1. Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.

Group I, claim(s) 1-7 & 15-21, drawn to pharmaceutical compositions comprising the human hANP natriuretic peptide of SEQ ID NO: 1, rat rANP peptide of SEQ ID NO: 2, human BNP peptide of SEQ ID NO: 4, frog ANP peptide of SEQ ID NO: 5, pig BNP peptide of SEQ ID NO: 6, rat BNP peptide of SEQ ID NO: 7 *or* the chick NP peptide of SEQ ID NO: 8, respectively, and methods of making these compositions by adding a pharmaceutical carrier. Note that each separate netriuretic peptide (e.g., as it relates to SEQ ID NOs: 1-8, etc) must further be elected to be fully responsive to this restriction (i.e., not species) election requirement.

Group II, claim(s) 8-14 & 22-25, drawn to methods of treating a Th1-mediated immune disease or regulating the Th1/Th2 balance in the immune system comprising administering a natriuretic peptide.

2. The inventions listed as Groups I-II do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

Application/Control Number: 10/560,378

Page 3

Art Unit: 1649

Group I is directed pharmaceutical compositions comprising a natriuretic peptide, which is the first product. However, because Kiemer et al (Annals of the Rheumatic Diseases, 2001) teach rat ANP, which meets the recited claim limitations, no special technical feature exists for Group I as defined by PCT Rule 13.2, because it does not define a contribution over the prior art. Group II is drawn to methods having different goals, method steps and starting materials, which do not require each other for their practice and do not share the same or a corresponding technical feature. Note that PCT Rule 13 does not provide for multiple products or methods within a single application. Because the technical feature of Group I is not a special technical feature, and because the technical features of the Group II inventions are not present in the Group I claims, unity of invention is lacking.

3. Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Application/Control Number: 10/560,378 Page 4

Art Unit: 1649

Conclusion

4. Any inquiry concerning this communication or earlier communications from the examiner should be directed to examiner Robert Hayes whose telephone number is (571) 272-0885. The examiner can normally be reached on Monday through Thursday from 9:00 AM to 5:00 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Jeffrey Stucker, can be reached on (571) 272-0911. The fax phone number for this Group is (571) 273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

/Robert C. Hayes, Ph.D./ Primary Examiner, Art Unit 1649 February 26, 2009